Alligator Bioscience AB ("Alligator" or the "Company") announced today that it is sharpening its primary focus on ...

Embryo-Fetal Toxicity ZIIHERA can cause fetal harm when administered to a pregnant woman. In literature reports, use of a HER2-directed antibody during p ...

The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and ...

Transaction valued at €3.5 millionThe partners have enjoyed a successful discovery collaboration since 2021LUND, SWEDEN / ACCESSWIRE / November 19, 2024 / Alligator Bioscience (STO:ATORX) today announ ...

ORION CORPORATION INVESTOR NEWS 19 NOVEMBER 2024 at 18.30 EET Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies Orion Corporation and Alligator Bioscience AB ...

ALLIGATOR-GOLD® and ALLIGATOR-FAB™, the powerful protein optimization strategy FIND® and the bispecific antibody format RUBY™, which drives rapid design and development of innovative drugs. Alligator ...

While bispecific antibodies tend to be well-tolerated for patients with multiple myeloma, there are still adverse effects clinicians should discuss with their patients. The use of bispecific ...

The bispecific antibodies market continues to grow due to the use of BsAbs in diagnostics. In general, bsAb is designed to bind a specific antigen and a detection moiety (e.g., horseradish peroxidase) ...

Merck & Co – known as MSD outside the US and Canada – has entered into an exclusive global licensing agreement worth over $3.2bn to advance LaNova Medicines’ investigational PD-1/VEGF bispecific ...

14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody ...